ESMO 2022 | FIRE-6: avelumab + FOLFIRI plus cetuximab followed by avelumab maintenance in untreated RASwt mCRC

Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses the results of the Phase II FIRE-6 trial which evaluated avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type (wt) colorectal cancer (CRC). With a median progression-free survival of 7.0 months, FIRE-6 did not reach its pre-specified endpoint. Avelumab maintenance after FOLFIRI plus cetuximab therefore is not effective to postpone disease progression after FOLFIRI plus cetuximab induction therapy in first-line RASwt mCRC patients.This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.